IMF Videos Search Content For Healthcare Professional (76) Healthcare Provider (75) Care Partner (65) Patient (65) Series - Any - ASCO/EHA (31) ASH (30) Ask Dr. Durie (16) Community Workshops (3) Emerging Therapies (12) Facebook Live (6) Health Equity (4) IMWG (3) Living Well with Myeloma (3) Myeloma in a Minute (2) Myeloma Made Simple (6) Myeloma University (9) Q&A (6) Recent News and Developments (2) Treatments (1) Trending Searches in Myeloma (1) Topics Clinical Trials (184) Financial Considerations (15) Frontline Therapy (81) Health Equity (33) Inspirational Stories (23) Insurance (6) Lab & Imaging Tests (68) Lifestyle (47) Mental & Emotional Health (28) Myeloma 101 (54) Myeloma in the News (7) Public Policy & Advocacy (17) Q&A's (41) Recorded Seminars & Workshops (14) Recorded Webinars (23) Relapse/Refractory Myeloma (135) Research Updates (192) Symptom Management (113) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (88) High-Risk Myeloma (38) High-risk Smoldering Myeloma (17) Late Relapse (4–6 Lines of Therapy) (101) MGUS (5) Newly Diagnosed (Pre-Treatment or First Treatment) (24) Smoldering Myeloma (13) Types of Therapy Immunomodulatory drugs (IMiDs) (31) Immunotherapies (CAR T; BiTE, etc.) (97) Monoclonal antibodies (33) Proteasome inhibitors (23) Stem cell transplant (24) Steroids (20) Supportive Care (36) Year Published 2026 (18) 2025 (22) 2024 (35) 2023 (39) 2022 (4) 2021 (4) 2020 (3) 2019 (2) 2018 (1) 2017 (1) 2016 (4) 2015 (2) Trusted Voices Dr. Joseph Mikhael (35) Dr. Brian GM Durie (15) Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO (5) Donna Catamero, ANP-BC, OCN, CCRC (3) Dr. María-Victoria Mateos (2) Dr. Saad Usmani (2) Dr. Sagar Lonial (1) Dr. Tom Martin (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance LINKER-MM1 Trial: Evaluating Linvoseltamab (REGN5458) in Patients with Relapsed or Refractory Multiple Myeloma June 14, 2023 ASCO/EHA Elranatamab: Extended Follow-up & Biweekly Admin for RRMM | MagnetisMM-3 Study June 13, 2023 ASCO/EHA What are the differences between CAR T-cell therapy and bispecific antibodies? April 13, 2023 Ask Dr. Durie Living Well with Myeloma Webinar - New Drugs in Myeloma – What, How and When? What Patients and Care Partners Need to Know March 30, 2023 Living Well with Myeloma Myeloma ACTION Month: Special Q&A with Dr. Joseph Mikhael March 22, 2023 Facebook Live Elranatamab in Combination with Daratumumab for Patients with Relapsed Refractory Multiple Myeloma: Phase 3 MagnetisMM-5 February 10, 2023 ASH Real World Efficacy and Toxicity of Selinexor: Importance of Dose Intensity and Post Progression Outcomes February 6, 2023 ASH Tocilizumab pre-treatment reduced cytokine release syndrome in relapsed/refractory multiple myeloma patients receiving cevostamab February 3, 2023 ASH Alnuctamab, a BCMA x CD3 T-Cell Engager, in Patients with Relapsed/Refractory Multiple Myeloma February 2, 2023 ASH Clinical Activity of BMS-986393, a CAR T cell therapy directed at GPRC5D, in Pts with RRMM February 1, 2023 ASH Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma: MagnetisMM-3 January 30, 2023 ASH Bispecifics Part 4: The Science of Bispecific Antibodies January 13, 2023 Emerging Therapies Load More
